Galapagos is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. The pipeline comprises Phase 3, 2, 1 studies, pre-clinical studies and discovery programs in inflammation, fibrosis and other indications. The company seeks to develop a robust portfolio of clinical-stage breakthrough therapies that have the potential to revolutionize existing treatment paradigms.
The Galapagos group, including fee-for-service subsidiairy Fidelta, has approximately 700 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, Switzerland, the US and Croatia.